ESMO 2022 Transgene presented exciting preclinical data on TG6050, an intravenous Invir.IO® oncolytic virus Donwload Press release (PDF) TG6002 en images

innovation box

Innovative technologies Push the boundaries of immunotherapy Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network. Discover our two therapeutic approaches Discover our technologies

TG4001 box

TG4001 A therapeutic vaccine in Phase II TG4001 targets HPV-induced anogenital cancers. More information


One patient, one cancer, one vaccine With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform. myvac® video Discover myvac®


A new generation of products These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer. Discover invir.IO®